Back to Search
Start Over
US FDA grants priority review status for Merck & Eisai's Keytruda plus Lenvima applications for advanced RCC and advanced endometrial carcinoma
- Source :
- PharmaBiz. May 7, 2021
- Publication Year :
- 2021
-
Abstract
- Merck, known as MSD outside the United States and Canada, and Eisai Inc. announced that the US Food and Drug Administration (FDA) has accepted and granted priority review for applications [...]
- Subjects :
- Eisai Inc. -- Technology application
Merck Research Laboratories -- Technology application
United States. Food and Drug Administration -- Technology application
Lenvima (Medication)
Keytruda (Medication)
Drug therapy
Technology application
Sunitinib -- Technology application
Carcinoma -- Drug therapy
Pembrolizumab -- Technology application
Lenvatinib -- Technology application
Pharmaceutical industry -- Technology application
Drug approval -- Technology application
Everolimus -- Technology application
Cancer -- Drug therapy
Subjects
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- PharmaBiz
- Publication Type :
- Periodical
- Accession number :
- edsgcl.661045860